435 related articles for article (PubMed ID: 18928402)
1. Akt/GSK3 signaling in the action of psychotropic drugs.
Beaulieu JM; Gainetdinov RR; Caron MG
Annu Rev Pharmacol Toxicol; 2009; 49():327-47. PubMed ID: 18928402
[TBL] [Abstract][Full Text] [Related]
2. [Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses].
Del'Guidice T; Beaulieu JM
Med Sci (Paris); 2010; 26(6-7):647-51. PubMed ID: 20619169
[TBL] [Abstract][Full Text] [Related]
3. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health.
Beaulieu JM
J Psychiatry Neurosci; 2012 Jan; 37(1):7-16. PubMed ID: 21711983
[TBL] [Abstract][Full Text] [Related]
4. Looking at lithium: molecular moods and complex behaviour.
Beaulieu JM; Caron MG
Mol Interv; 2008 Oct; 8(5):230-41. PubMed ID: 19015387
[TBL] [Abstract][Full Text] [Related]
5. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
Sutton LP; Rushlow WJ
Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
[TBL] [Abstract][Full Text] [Related]
6. The Akt-GSK-3 signaling cascade in the actions of dopamine.
Beaulieu JM; Gainetdinov RR; Caron MG
Trends Pharmacol Sci; 2007 Apr; 28(4):166-72. PubMed ID: 17349698
[TBL] [Abstract][Full Text] [Related]
7. A beta-arrestin 2 signaling complex mediates lithium action on behavior.
Beaulieu JM; Marion S; Rodriguiz RM; Medvedev IO; Sotnikova TD; Ghisi V; Wetsel WC; Lefkowitz RJ; Gainetdinov RR; Caron MG
Cell; 2008 Jan; 132(1):125-36. PubMed ID: 18191226
[TBL] [Abstract][Full Text] [Related]
8. An emerging role for Wnt and GSK3 signaling pathways in schizophrenia.
Singh KK
Clin Genet; 2013 Jun; 83(6):511-7. PubMed ID: 23379509
[TBL] [Abstract][Full Text] [Related]
9. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers.
Del' Guidice T; Beaulieu JM
J Recept Signal Transduct Res; 2015 Jun; 35(3):224-32. PubMed ID: 26459714
[TBL] [Abstract][Full Text] [Related]
10. Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models.
Luo DZ; Chang CY; Huang TR; Studer V; Wang TW; Lai WS
Sci Rep; 2020 Jan; 10(1):647. PubMed ID: 31959776
[TBL] [Abstract][Full Text] [Related]
11. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
12. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain.
Ozaita A; Puighermanal E; Maldonado R
J Neurochem; 2007 Aug; 102(4):1105-14. PubMed ID: 17484726
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
Cole AR
FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
[TBL] [Abstract][Full Text] [Related]
14. Validating GSK3 as an in vivo target of lithium action.
O'Brien WT; Klein PS
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1133-8. PubMed ID: 19754466
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic drug actions on gene modulation and signaling mechanisms.
Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotics in the treatment of bipolar disorder.
Singh J; Chen G; Canuso CM
Handb Exp Pharmacol; 2012; (212):187-212. PubMed ID: 23129333
[TBL] [Abstract][Full Text] [Related]
17. GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption.
Watcharasit P; Thiantanawat A; Satayavivad J
J Appl Toxicol; 2008 May; 28(4):466-74. PubMed ID: 17849503
[TBL] [Abstract][Full Text] [Related]
18. Serotonin/dopamine interaction--focus on 5-HT2C receptor, a new target of psychotropic drugs.
Di Giovanni G; Di Matteo V; Esposito E
Indian J Exp Biol; 2002 Dec; 40(12):1344-52. PubMed ID: 12974395
[TBL] [Abstract][Full Text] [Related]
19. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs.
Beaulieu JM
Int J Neuropsychopharmacol; 2007 Feb; 10(1):3-6. PubMed ID: 16784549
[No Abstract] [Full Text] [Related]
20. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
Dokken BB; Sloniger JA; Henriksen EJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
